Mind Medicine Mindmed Inc (MNMD) Stock Price, Quote & News

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: www.mindmed.co

Address:

One World Trade Center, Suite 8500, New York, United States

PsychedStocks Dec. 1 at 2:26 PM

$CYBN $CMPS $ATAI $MNMD $SPY Bryan Johnson’s 5g mushroom trip livestream in case you missed it yesterday! Was awesome to see the love he was sharing with his family. https://x.com/bryan_johnson/status/1995195043121180703?s=46&t=bCeLK1bAn4Beo5i6OzNGcA

0 · Reply

TheCaptainJ Nov. 29 at 1:16 PM

$MNMD here since .30 ever a reverse split but look at this baby now! Baby made a boom boom rocket ship!

1 · Reply

MoneyGroupLLC Nov. 29 at 12:33 PM

Enter: $MNMD Calls Strike Price: $13 Expiry Date: DEC 19 2025 Buy in Price: $0.64 - $0.95 Sell Price: $1.06 Profit : +66% (Turn every $1 into $1.66) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

twiggs462 Nov. 28 at 11:29 PM

$MNMD DEA Moves To Boost Production Of Psychedelics To Explore Therapeutic Potential For PTSD And Depression https://www.marijuanamoment.net/dea-moves-to-boost-production-of-psychedelics-to-explore-therapeutic-potential-for-ptsd-and-depression/ Regarding the filing by MindMed in regards to Psilocin (https://www.reddit.com/r/MindMedInvestorsClub/comments/1p5pz9x/quietly_filling_the_psilos_understanding/)... This bodes well: "The proposed production goal for psilocybin rose from 30,000 grams this year to 40,000 grams in 206, while the psilocyn quota increased from 36,000 grams to 48,000 grams." in 2026 the production flipped to more psilocin/psilocyn to psilocybin... hmmmmm 🤔

0 · Reply

BobbyCucumber Nov. 28 at 2:49 PM

$MNMD

0 · Reply

BullsVSBearsVSYoMomma Nov. 28 at 2:41 PM

$MNMD

0 · Reply

dlawler_99 Nov. 28 at 1:59 AM

$MNMD Happy Thanksgiving everyone, even Goral:)). Stay safe and joyful!

1 · Reply

MoneyGroupLLC Nov. 27 at 12:34 PM

Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.87 - $0.91 Sell Price: $1.64 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Woofofwallstreet69 Nov. 26 at 3:47 PM

$MNMD should see gradual climb til Q2 2026 for anticipation of results from trials

1 · Reply

tskiba5 Nov. 26 at 2:51 PM

$MNMD several companies registering to import/manufacture psilocybin

1 · Reply

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 24 days ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 26 days ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 4:01 PM EST - 27 days ago

MindMed Announces New Employee Inducement Grant

Nov 3, 2025, 7:01 AM EST - 4 weeks ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 4 weeks ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 4 weeks ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 4 weeks ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 14, 2025, 12:28 PM EDT - 6 weeks ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 13, 2025, 2:54 PM EDT - 6 weeks ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 22, 2025, 4:01 PM EDT - 2 months ago

MindMed Announces New Employee Inducement Grants

Sep 19, 2025, 7:00 AM EDT - 2 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 3 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 3 months ago

MindMed to Participate in September Investor Conferences

Aug 12, 2025, 3:43 AM EDT - 3 months ago

If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today

Aug 7, 2025, 5:25 AM EDT - 4 months ago

1 Reason to Buy MindMed (MNMD)

Aug 1, 2025, 6:43 PM EDT - 4 months ago

MindMed (MNMD) Q2 Net Loss Jumps 625%

Jul 31, 2025, 9:48 PM EDT - 4 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:01 PM EDT - 4 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 4 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jun 4, 2025, 7:02 AM EDT - 6 months ago

Why Mind Medicine Gave Investors a Powerful Buzz in May

May 28, 2025, 7:00 AM EDT - 6 months ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 6 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 20, 2025, 5:33 PM EDT - 6 months ago

Why Mind Medicine Stock Vaulted More Than 8% Higher Today

May 13, 2025, 7:00 AM EDT - 7 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 7 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 7 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 7 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 8 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 9 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 9 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 9 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 9 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 10 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 14, 2025, 3:35 PM EST - 10 months ago

Why Mind Medicine Stock Is Skyrocketing Today

Feb 4, 2025, 7:00 AM EST - 10 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 10 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 7, 2025, 2:25 PM EST - 11 months ago

Why Mind Medicine Stock Is Soaring Today

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

PsychedStocks Dec. 1 at 2:26 PM

0 · Reply

TheCaptainJ Nov. 29 at 1:16 PM

$MNMD here since .30 ever a reverse split but look at this baby now! Baby made a boom boom rocket ship!

1 · Reply

MoneyGroupLLC Nov. 29 at 12:33 PM

0 · Reply

twiggs462 Nov. 28 at 11:29 PM

0 · Reply

BobbyCucumber Nov. 28 at 2:49 PM

$MNMD

0 · Reply

BullsVSBearsVSYoMomma Nov. 28 at 2:41 PM

$MNMD

0 · Reply

dlawler_99 Nov. 28 at 1:59 AM

$MNMD Happy Thanksgiving everyone, even Goral:)). Stay safe and joyful!

1 · Reply

MoneyGroupLLC Nov. 27 at 12:34 PM

0 · Reply

Woofofwallstreet69 Nov. 26 at 3:47 PM

$MNMD should see gradual climb til Q2 2026 for anticipation of results from trials

1 · Reply

tskiba5 Nov. 26 at 2:51 PM

$MNMD several companies registering to import/manufacture psilocybin

1 · Reply

Iightning Nov. 26 at 3:51 AM

1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com

0 · Reply

MoneyGroupLLC Nov. 26 at 2:50 AM

Enter: $MNMD Calls Strike Price: $12 Expiry Date: DEC 19 2025 Buy in Price: $0.80 - $0.85 Sell Price: $1.30 Profit : +62% (Turn every $1 into $1.62) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

BankOnTheFuture Nov. 25 at 8:43 PM

$CMPS $ATAI $CYBN $MNMD

0 · Reply

blipper Nov. 25 at 3:09 PM

$MNMD hey king

0 · Reply

Iightning Nov. 25 at 1:57 PM

1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 2:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $MNMD Dec 19 $12 Call | Enter: $0.80 Exit: $1.21 | Profit: 51.20% ROI | https://1ightning.com

0 · Reply

dsfwf Nov. 25 at 12:01 AM

$MNMD closed at $11.87 (+10.02%), showing strong momentum with increasing volume.If it can hold above 11.5, it may continue pushing toward the previous high of $14.43.THE trend is looking bullish worth keeping an eye on

0 · Reply

BullsVSBearsVSYoMomma Nov. 24 at 10:12 PM

$MNMD Gap up filled now. Run it

2 · Reply

zcurrency Nov. 24 at 9:47 PM

$MNMD https://x.com/mindmedco/status/1992969954748969153?s=46&t=lLi_3TjkIo8AfK12UxM3Vg

0 · Reply

dlawler_99 Nov. 24 at 8:56 PM

$MNMD

0 · Reply

dlawler_99 Nov. 24 at 8:56 PM

$MNMD resistance is now support🤯

0 · Reply

Tradetime3472 Nov. 24 at 8:28 PM

$ATAI $CMPS $CYBN $MNMD and $PBM is the only Nasdaq listed company that has ibogaine operations straight from the source in Africa. Most likely will get a part of the $50M Texas ibogain fund

2 · Reply

Market Cap	1.25B
Revenue (ttm)	0.00
Net Income (ttm)	-108.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	928,000
Avg Vol	2,016,554
Day's Range	N/A - N/A
Shares Out	98.51M
Stochastic %K	94%
Beta	2.57
Analysts	Strong Sell
Price Target	$25.64